citrus bioflavones (quercetin)

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• age-related cognitive decline [Insufficient Evidence]
• allergic rhinitis [Insufficient Evidence]
• Alzheimer dz [Insufficient Evidence]
• aphthous ulcer (canker sores) [Insufficient Evidence]
• asthma [Insufficient Evidence]
• atherosclerosis [Insufficient Evidence]
• athletic performance [Possibly Ineffective]
• autism spectrum disorder [Insufficient Evidence]
• beta-thalassemia [Insufficient Evidence]
• BPH [Insufficient Evidence]
• cancer [Insufficient Evidence]
• cancer prevention, colorectal [Insufficient Evidence]
• cancer prevention, lung [Insufficient Evidence]
• cancer prevention, ovarian [Insufficient Evidence]
• cancer prevention, pancreatic [Insufficient Evidence]
• cardiovascular dz prevention [Insufficient Evidence]
• cataracts [Insufficient Evidence]
• chronic fatigue syndrome [Insufficient Evidence]
• chronic venous insufficiency [Insufficient Evidence]
• COVID-19 [Insufficient Evidence]
• cystitis, chemo-induced [Insufficient Evidence]
• depression [Insufficient Evidence]
• diabetes mellitus, type 2 [Insufficient Evidence]
• exercise-induced muscle damage [Insufficient Evidence]
• exercise-induced respiratory infection prevention [Insufficient Evidence]
• flushing, niacin-induced [Insufficient Evidence]
• gout [Insufficient Evidence]
• herpes labialis (cold sores) [Insufficient Evidence]
• HTN [Insufficient Evidence]
• hypercholesterolemia [Insufficient Evidence]
• renal transplant [Insufficient Evidence]
• metabolic syndrome [Insufficient Evidence]
• nephropathy, contrast-induced [Insufficient Evidence]
• obesity [Insufficient Evidence]
• oral mucositis [Insufficient Evidence]
• peptic ulcer [Insufficient Evidence]
• physical performance [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• prostatitis, chronic [Insufficient Evidence]
• rheumatoid arthritis [Insufficient Evidence]
• schizophrenia [Insufficient Evidence]
• urethral syndrome [Insufficient Evidence]
• URI [Insufficient Evidence]
• UTI [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note, COVID-19

[no scientific data for COVID-19]

Info: see Herb & Supplement Remedy Use in COVID-19 Resources

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

age-related cognitive decline

[Insufficient Evidence]

Dose: 110 mg PO qd

allergic rhinitis, adult pts

[Insufficient Evidence]

Dose: 100 mg PO bid

allergic rhinitis, peds pts

[Insufficient Evidence]

Dose: 150 mg PO qd x8-12wk; Info: for pts 6-12 yo; used w/ antihistamine in first 4wk of tx

aphthous ulcer (canker sores)

[Insufficient Evidence]

Dose: apply cream topically tid

asthma

[Insufficient Evidence]

Dose: 250-500 mg PO qd; Info: used w/ conventional tx

autism spectrum disorder, peds pts

[Insufficient Evidence]

Dose: 7 mg/kg/dose PO qd; Info: for pts 4-10 yo

beta-thalassemia

[Insufficient Evidence]

Dose: 500 mg PO qd

COVID-19

[Insufficient Evidence]

Dose: 200 mg PO tid x7 days, then 200 mg PO bid x7 days; Alt: 200 mg PO bid x30 days; 500 mg PO tid x7 days, then 500 mg PO bid x7 days; 500 mg PO bid x7 days; 260-1000 mg PO qd x7-30 days; Info: used w/ standard tx

cystitis, chemo-induced

[Insufficient Evidence]

Dose: 400 mg PO qam; Start: 7 days before 1st instillation

exercise-induced muscle damage

[Insufficient Evidence]

Dose: 500 mg PO bid

exercise-induced respiratory infection prevention

[Insufficient Evidence]

Dose: 500 mg PO bid

HTN

[Insufficient Evidence]

Dose: 100-1000 mg PO qd; Alt: 1095 mg PO x1

physical performance

[Insufficient Evidence]

Dose: 200-500 mg PO qd

polycystic ovary syndrome

[Insufficient Evidence]

Dose: 500 mg PO bid; Alt: 500 mg PO qd

prostatitis, chronic

[Insufficient Evidence]

Dose: 500 mg PO bid

renal transplant

[Insufficient Evidence]

Dose: 20 mg PO qd-bid; Start: w/in 24h of renal transplant; Info: used w/ anti-rejection tx

rheumatoid arthritis

[Insufficient Evidence]

Dose: 500 mg PO qd

URI

[Insufficient Evidence]

Dose: 1000 mg PO qd